Youyi Peng;Lawrence P. Wennogle;Qiang Zhang;John Tomesch
发明人:
Youyi Peng,Lawrence P. Wennogle,Qiang Zhang,John Tomesch
申请号：
US14127699
公开号：
US09108949B2
申请日:
2012.06.22
申请国别(地区):
US
年份:
2015
代理人:
摘要：
It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.
